Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print      Mail a friend       Annual reports

Monday 23 September, 2019

AstraZeneca PLC

Qtrilmet recommended for approval in EU by CHMP

RNS Number : 2444N
AstraZeneca PLC
23 September 2019
 

23 September 2019 07:00 BST

 

Qtrilmet recommended for approval in EU by

CHMP for the treatment of type-2 diabetes

 

AstraZeneca today announced that Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) modified-release tablets have been recommended for marketing authorisation in the European Union for the treatment of adults with type-2 diabetes (T2D).

 

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on data from five Phase III trials which evaluated combinations of Forxiga (dapagliflozin) and Onglyza (saxagliptin) on a background of metformin in patients with inadequately-controlled T2D. The primary endpoint in these trials was mean change from baseline in HbA1c (average blood glucose levels) at week 24 or 52.

 

Across the trials, the combination of Forxiga, Onglyza and metformin was superior in reducing HbA1c versus Forxiga combined with metformin, Onglyza combined with metformin, or glimepiride combined with metformin. The combination of Forxiga, Onglyza and metformin with or without sulphonylurea (SU) was non-inferior to the combined use of insulin and metformin with or without SU in reducing HbA1c.

 

The safety results of the individual medicines in these trials were consistent with their known profile.

 

The CHMP recommended the marketing authorisation for Qtrilmet to improve glycaemic control when metformin with or without SU and either saxagliptin or dapagliflozin does not provide adequate glycaemic control, or when T2D patients are already being treated with metformin, saxagliptin and dapagliflozin.

 

Qtrilmetis approved in the US under the name Qternmet XR as an adjunct to diet and exercise to improve glycaemic control in adults with T2D.

 

About Qtrilmet

Qtrilmetis a once-daily, oral medicine comprised of the selective sodiumglucose co-transporter 2 (SGLT2) inhibitor Forxiga, the dipeptidyl peptidase4 (DPP4) inhibitor Onglyza and metformin hydrochloride extended release indicated as treatment in adults with T2D.

 

About AstraZeneca in CVRM

Cardiovascular, Renal & Metabolism (CVRM) together forms one of AstraZeneca's three therapy areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling co-morbidities. The Company's ambition is to modify or halt the natural course of CVRM diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of patients worldwide.

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism (CVRM) and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

 

Media Relations

 

 

 

Gonzalo Viña

 

+442037495916

 

Rob Skelding

Oncology

+44 203 749 5821

 

Rebecca Einhorn

Oncology

+1 301 5184122

 

Matt Kent

BioPharmaceuticals

+44 203 749 5906

 

Jennifer Hursit

Other

+44 203 749 5762

 

Christina Malmberg Hägerstrand

Sweden

+46 8 552 53 106

 

Michele Meixell

US

+1 302 885 2677

 

 

 

 

 

Investor Relations

 

 

 

Thomas Kudsk Larsen

 

+44 203 749 5712

 

Henry Wheeler

Oncology

+44 203 749 5797

 

Christer Gruvris

BioPharmaceuticals (CV, metabolism)

+44 203 749 5711

 

Nick Stone

BioPharmaceuticals (respiratory, renal)

+44 203 749 5716

 

Josie Afolabi

Other medicines

+44 203 749 5631

 

Craig Marks

Finance, fixed income

+44 7881 615 764

 

Jennifer Kretzmann

Corporate access, retail investors

+44 203 749 5824

 

US toll-free

 

+1 866 381 72 77

 

 

 

 

           

Adrian Kemp
Company Secretary
AstraZeneca PLC


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCCKNDDPBKKACB

a d v e r t i s e m e n t